A daily, rules-based strategy that mixes volatility hedges (UVXY/SQQQ), a biotech tilt (LABU) with a dynamic top-3 mega-cap DeETF basket, all under a SPY-uptrend filter and short-term momentum checks. High-risk, levered exposure with a focus on tech/biotech, rebalanced each day.

- The strategy is daily-rebalanced and lives in the US equities space, with a strong emphasis on momentum signals and trend filters. - Trend filter: It first checks whether SPY (the broad US market proxy) is above its 200-day moving average. If not, the system reduces or avoids aggressive bets. - Volatility hedge path: If certain short-term momentum signals indicate extreme market stress or overheating (captured by RSI readings on UVXY against major benchmarks like XLK, SPY, VTV, VOX), the model allocates to volatility-related ETFs (UVXY for rising volatility, SQQQ as an inverse Nasdaq bet) to hedge or capitalize on fear spikes. These entries depend on several cascading RSI checks (e.g., UVXY RSI above a high threshold relative to benchmarks). - LABU + DeETF path: If biotech momentum looks favorable or oversold conditions align, the system opens LABU (3x biotech levered ETF) positions. It also includes a DeETF component, which builds a small basket from a list of large-cap stocks (MSFT, AAPL, NVDA, AMZN, GOOGL, META, BRK/B, LLY, TSLA, PG, COST, MRK, ABBV, AMD, ADBE) by selecting the top performers over a 20-day window. This DeETF basket receives a defined weight (a substantial share of the LABU-related allocation) to diversify risk within the LABU/DeETF leg. - Weighting and hierarchy: The system uses explicit weight splits (e.g., DeETF getting 70% of a sub-leg, with LABU getting the remainder or a separate 40% allocation in some branches) to control exposure across the different strategy blades. - Signals rely on a mix of indicators: current price vs 200-day average, short-window RSI comparisons (10-day RSI on UVXY, LABU, and related proxies), and short-term cumulative returns (e.g., 1-day, 5-day, 20-day windows) to time entries. - The target assets include leveraged and inverse ETFs (UVXY, SQQQ), biotech levered ETF (LABU), and a dynamic DeETF basket composed of mega-cap names. The intent is to capture upside in trends while hedging downside with volatility bets, all while occasionally tilting toward a Biotech momentum play via LABU and its supporting DeETF. - Rebalance is daily, which means positions can change every trading day as signals evolve, amplifying both potential gains and losses.

Out-of-sample this strategy targets higher upside than SPY: ~32.8% annualized return with positive alpha, aided by volatility hedges and biotech/mega-cap tilt. Higher potential gains, but expect larger drawdowns in stressed markets.